TScan Therapeutics, Inc. (TCRX) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	7.1M	10.3M	2.8M	21.0M	13.5M
Cost of Revenue	693.0K	2.9M	—	—	—
Gross Profit	6.4M	7.5M	2.8M	21.0M	13.5M
Operating Expenses
R&D Expense	97.0M	114.2M	107.3M	88.2M	59.8M
SG&A Expense	29.8M	32.0M	29.6M	25.5M	20.4M
General & Admin Expense	29.8M	32.0M	29.6M	25.5M	20.4M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	139.0K	(2.9M)	728.0K	862.0K	—
Total Operating Expenses	127.0M	143.3M	137.6M	114.5M	80.2M
Cost and Expenses	127.7M	146.1M	137.6M	114.5M	80.2M
Operating Income (EBIT)	(120.5M)	(135.8M)	(134.8M)	(93.5M)	(66.6M)
Non-Operating
Interest Income	5.6M	8.8M	12.1M	8.0M	1.6M
Interest Expense	2.8M	2.8M	3.7M	3.8M	1.2M
Net Interest Income	2.8M	6.0M	8.4M	4.2M	415.0K
Other Non-Op Income/Expense	2.8M	6.0M	7.3M	4.2M	415.0K
Non-Operating Income (excl Interest)	(5.6M)	(8.8M)	(11.0M)	(8.0M)	(1.6M)
EBT (Pre-Tax Income)	(117.7M)	(129.8M)	(127.5M)	(89.2M)	(66.2M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(117.7M)	(129.8M)	(127.5M)	(89.2M)	(66.2M)
Earnings from Cont. Ops	(117.7M)	(129.8M)	(127.5M)	(89.2M)	(66.2M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(117.7M)	(129.8M)	(127.5M)	(89.2M)	(66.2M)
Per Share
Basic EPS	($0.91)	($1.00)	($1.14)	($1.36)	($2.74)
Diluted EPS	($0.91)	($1.00)	($1.14)	($1.36)	($2.74)
Revenue Per Share	$0.05	$0.08	$0.03	$0.32	$0.56
Shares
Basic Shares Outstanding	129.9M	129.9M	112.0M	65.6M	24.0M
Diluted Shares Outstanding	129.9M	129.9M	112.0M	65.6M	24.0M
Profitability Metrics
EBITDA	(112.0M)	(124.1M)	(119.7M)	(80.1M)	(59.9M)
D&A	2.9M	2.9M	4.1M	5.4M	5.1M
EBIT	(114.9M)	(127.0M)	(123.8M)	(85.5M)	(65.0M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026